Analogues of VDAC1-derived peptides

Patent metadata

Field	Value
Publication number	US-11634465-B2
Application number	US-202017039042-A
Country	US
Kind code	B2
Filing date	Sep 30, 2020
Priority date	Sep 3, 2015
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.

First claim

What is claimed is:

1. A method of treating non-alcoholic fatty liver disease (NAFLD) and/or a symptom associated with NAFLD, the method comprises administering to a subject diagnosed to have NAFLD a therapeutically effective amount of a pharmaceutical composition comprising a synthetic peptide, which comprises (i) an analogue of VDAC1-derived peptide, wherein the analogue comprises the amino acid sequence set forth in SEQ ID NO:2 and is completely inverso modified, and (ii) a recognition and/or localization peptide comprising the amino acid sequence set forth in SEQ ID NO:8, thereby treating the non-alcoholic fatty liver disease (NAFLD) and/or the symptom associated thereto.

2. The method of claim 1 , wherein the analogue comprises the amino acid sequence set forth in SEQ ID NO:3.

3. The method of claim 1 , wherein the recognition and/or localization peptide is selected from an all L-stereoisomeric peptide and an all D-stereoisomeric peptide.

4. The method of claim 3 , wherein the recognition and/or localization peptide is connected to the N- or the C-terminus of the analogue of VDAC1-derived peptide directly or via a linker sequence.

5. The method of claim 4 , wherein the synthetic peptide further comprises the amino acid sequence set forth in SEQ ID NO:11 and the amino acid sequence set forth in SEQ ID NO:12, each independently located at the C- or N-terminus of the analogue of VDAC1-derived peptide.

6. The method of claim 4 , wherein the synthetic peptide further comprises the amino acid sequence set forth in SEQ ID NO:12 and the amino acid sequence set forth in SEQ ID NO:13, each independently located at the C- or N-terminus of the analogue of VDAC1-derived peptide.

7. The method of claim 6 , wherein the synthetic peptide comprises the amino acid sequence set forth in SEO ID NO:14.

8. The method of claim 1 , wherein the NAFLD is selected from the group consisting of non-alcoholic steatosis and non-alcoholic steohepatitis (NASH).

9. The method of claim 1 , wherein the symptom associated with NAFLD is selected from the group consisting of fat droplet accumulation, inflammation, fibrosis, hepatocyte cell death and any combination thereof.

Assignees

• B G Negev Technologies And Applications Ltd At Ben Gurion Univ
• Nat Inst Biotechnology Negev Ltd
• B G Negev Tech And Applications Ltd At Ben Gurion Unlversity

Inventors

• Shoshan-Barmatz Varda

Classifications

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2319/10

  containing a tag for extracellular membrane crossing, e.g. TAT or VP22 · CPC title

• C07K14/79

  Transferrins, e.g. lactoferrins, ovotransferrins · CPC title